TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9581713

Group type: EXPERIMENTAL
Intervention: Stenting of the infarct-related artery (IRA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Optimal primary angioplasty (PTCA)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Stenting of the IRA
Number of subjects: 150
Study: 7520188

Group type: EXPERIMENTAL
Intervention: Aprotinin (140 mg primed in ECC pump, continuous IV perfusion at 70 mg/h)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 110
Study: 2645550

Group type: EXPERIMENTAL
Intervention: Apraclonidine 1.0%
Number of subjects: 18

Group type: COMPARATOR
Intervention: Dipivefrin 0.1%
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29360701

Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Extracorporeal anastomosis
Number of subjects: 60
Study: 26498428

Group type: EXPERIMENTAL
Intervention: Constant-current (CC) stimulation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Constant-voltage (CV) stimulation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mixed implants (CC after CV replacement)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: IPG replacement procedure
Number of subjects: 19
Study: 26335133

Group type: EXPERIMENTAL
Intervention: Self-assessment of vision
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Self-assessment of hearing
Number of subjects: 93
Study: 24352414

Group type: EXPERIMENTAL
Intervention: Computerized working memory training (25-day training program at school)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 67
Study: 20934573

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study: 18831859

Group type: EXPERIMENTAL
Intervention: Loratadine, 10 mg, once daily
Number of subjects: 835

Group type: COMPARATOR
Intervention: Fexofenadine, 60 mg, twice daily
Number of subjects: 835

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 835
Study: 16115151

Group type: EXPERIMENTAL
Intervention: TRAP Vascular Filtration System (VFS)
Number of subjects: 467

Group type: COMPARATOR
Intervention: Control (no TRAP device)
Number of subjects: 467
Study: 12146000

Group type: EXPERIMENTAL
Intervention: Exemestane 0.5-50 mg/day after breakfast for 7 days
Number of subjects: 32
Study: 10586564

Group type: EXPERIMENTAL
Intervention: Portex Profile Soft‐Seal Cuff (PSSC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Portex Profile Cuff (PC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mallincrodt Lo‐Contour (LC)
Number of subjects: 30
Study: 7768247

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg once daily)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Slow release nifedipine (20 mg twice daily)
Number of subjects: 320
Study: 2375291

Group type: EXPERIMENTAL
Intervention: Supplemented preterm human milk with bovine milk protein, calcium, phosphorus, and sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsupplemented preterm human milk
Number of subjects: 0
Study: 7023173

Group type: EXPERIMENTAL
Intervention: PGE2 tablets (ProstinR)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Oxytocin intravenously
Number of subjects: 471

Group type: COMPARATOR
Intervention: Primary amniotomy
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: PGE2
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 471

Group type: COMPARATOR
Intervention: PGE2 and Oxytocin
Number of subjects: 471
Study: 30919006

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 48
Study: 28662834

Group type: EXPERIMENTAL
Intervention: App with remote support
Number of subjects: 80

Group type: COMPARATOR
Intervention: Paper handouts
Number of subjects: 80
Study: 25872126

Group type: EXPERIMENTAL
Intervention: Community-based model of care
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 65
Study: 24093711

Group type: EXPERIMENTAL
Intervention: Local tenoxicam injection (1 mL of tenoxicam 20 mg/2 mL and 1 mL of 2% lidocaine)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Corticosteroid injection (1 mL containing 40 mg of methylprednisolone acetate and 1 mL of 2% lidocaine)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Comparison between tenoxicam and corticosteroid groups
Number of subjects: 61
Study: 21628305

Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 0
Study: 19462320

Group type: EXPERIMENTAL
Intervention: Mare's milk (250 ml daily for 16 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (250 ml daily for 16 weeks)
Number of subjects: 23
Study: 17920504

Group type: EXPERIMENTAL
Intervention: Acetaminophen (650 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ibuprofen (400 mg)
Number of subjects: 33
Study: 15257848

Group type: EXPERIMENTAL
Intervention: Heart disease prevention program (12 weekly sessions on lifestyle change and goal setting)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (32 participants)
Number of subjects: 76
Study: 12479189

Group type: EXPERIMENTAL
Intervention: M6G
Number of subjects: 144

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 144
Study: 9526208

Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 48

Group type: COMPARATOR
Intervention: No suction drainage
Number of subjects: 48
Study: 8031164

Group type: EXPERIMENTAL
Intervention: Group A: 400 mg of UFT orally for 7 days preoperatively, bolus 20 mg of MMC on the day of operation, bolus 10 mg of MMC the day after operation, followed by 800 mg of FT intravenously for 2 weeks and daily oral administration of 400 mg of UFT thereafter
Number of subjects: 35

Group type: COMPARATOR
Intervention: Group B: Bolus 20 mg of MMC on the day of surgery, bolus 10 mg the day after surgery, and 400 mg of UFT orally daily from 2 weeks after surgery
Number of subjects: 35

Group type: COMPARATOR
Intervention: Group C: 400 mg of UFT alone daily orally from 2 weeks after surgery
Number of subjects: 35
Study: 3136064

Group type: EXPERIMENTAL
Intervention: 300 mg disopyramide
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 800 mg tocainide
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 300 mg flecainide
Number of subjects: 23
Study: 30132751

Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 500

Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 500
Study: 28888094

Group type: EXPERIMENTAL
Intervention: Group B (100‐kVp and iodixanol 270 mg/mL with ASIR 40%)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Group A (120‐kVp and iopromide 370 mg/mL with FBP)
Number of subjects: 136
Study: 26180221

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 127
Study: 23111827

Group type: EXPERIMENTAL
Intervention: PCL-preserving group (42 knees)
Number of subjects: 90

Group type: COMPARATOR
Intervention: PCL-sacrificing group (44 knees)
Number of subjects: 90
Study: 21476961

Group type: EXPERIMENTAL
Intervention: LDL-C target of < 100 mg/dl
Number of subjects: 1123

Group type: COMPARATOR
Intervention: LDL-C target of < 130 mg/dl
Number of subjects: 1123
Study: 19593175

Group type: EXPERIMENTAL
Intervention: OFC (olanzapine/fluoxetine combination)
Number of subjects: 114

Group type: COMPARATOR
Intervention: OLZ (olanzapine monotherapy)
Number of subjects: 114
Study: 16551905

Group type: EXPERIMENTAL
Intervention: 66% N2O with isoflurane
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 66% N2O with sevoflurane
Number of subjects: 90

Group type: COMPARATOR
Intervention: isoflurane alone
Number of subjects: 90

Group type: COMPARATOR
Intervention: sevoflurane alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 3 microg/kg IV fentanyl
Number of subjects: 90
Study: 12919456

Group type: EXPERIMENTAL
Intervention: Nutritional education and implementation of a nutritional programme
Number of subjects: 176
Study: 10862642

Group type: EXPERIMENTAL
Intervention: High-flux dialysis
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low-flux dialysis
Number of subjects: 48
Study: 9112219

Group type: EXPERIMENTAL
Intervention: 1-2.5 x 10(6) CD34+ cells/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: greater than 2.5 x 10(6) CD34+ cells/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Threshold dose of 1 x 10(6) CD34+ cells/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CFU‐GM and CD34+ cells/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prior chemotherapy cycles
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CD34+ cell enumeration
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CFU‐GM clonogenic assays
Number of subjects: 45
Study: 7901248

Group type: EXPERIMENTAL
Intervention: Topical diphenylcyclopropenone (DPCP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Topical 5% minoxidil
Number of subjects: 15
Study: 3306128

Group type: EXPERIMENTAL
Intervention: Risk-adapted therapy
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Intermediate dose Methotrexate
Number of subjects: 611
Study: 31820537

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (97/103 mg b.i.d.)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 286
Study: 29099231

Group type: EXPERIMENTAL
Intervention: HIIT (8 × 2 minutes at 90% peak power output)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: supra-HIIT (8 × 20 seconds at 170% peak power output)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 48
Study: 28553078

Group type: EXPERIMENTAL
Intervention: Metformin extended release (XR)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Metformin immediate release (IR)
Number of subjects: 253
Study: 26169960

Group type: EXPERIMENTAL
Intervention: Strict treatment of CVD risk factors and lifestyle recommendations as per a prespecified protocol.
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Lipid- and/or blood pressure-lowering drugs prescribed to 69% of patients.
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Dietary advice given to 42% of patients.
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Physical exercise advised to 67% of patients.
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Adherence to lifestyle recommendations across CVD risk groups.
Number of subjects: 111
Study: 23046107

Group type: EXPERIMENTAL
Intervention: Progestin (5 mg medroxyprogesterone acetate/day for 30 days)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo (one pill/day for 30 days)
Number of subjects: 216
Study: 20675975

Group type: EXPERIMENTAL
Intervention: MS-sNT (morphine sulfate and naltrexone hydrochloride extended release capsules)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study: 18212335

Group type: EXPERIMENTAL
Intervention: High elaboration (need for cognition, personal relevance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low elaboration
Number of subjects: 0
Study: 20393176

Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa (20 mg/kg biweekly for 78 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 16392706

Group type: EXPERIMENTAL
Intervention: Rice diet (protein, 6.3 g; fat, 0.9 g; CHO, 79.3 g; energy, 368 kcal)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bread diet (protein, 15.7 g; fat, 5.8 g; CHO, 79.2 g; energy, 450 kcal)
Number of subjects: 10
Study: 11870127

Group type: EXPERIMENTAL
Intervention: Presence of HSP 60 IgA Ab in seminal fluid (total positive 6.9%)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Seminal IgA Ab to human HSP 60
Number of subjects: 202
Study: 9758298

Group type: EXPERIMENTAL
Intervention: Type-I atypical lymphocytes (AL) detected in cerebrospinal fluid (CSF)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Type-I atypical lymphocytes (AL)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Type-II atypical lymphocytes (AL)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Presence of type-I atypical lymphocytes (AL) in CSF
Number of subjects: 148

Group type: COMPARATOR
Intervention: Presence of type-II atypical lymphocytes (AL)
Number of subjects: 148
Study: 9316692

Group type: EXPERIMENTAL
Intervention: Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Controlled release levodopa/carbidopa 50/200
Number of subjects: 9
Study: 2853961

Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: enalapril 5 mg orally 3 h before
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 29883070

Group type: EXPERIMENTAL
Intervention: Sitagliptin (SITA group; n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Insulin alone (CONT group; n = 20)
Number of subjects: 40
Study: 27807604

Group type: EXPERIMENTAL
Intervention: Cariprazine (1.5-4.5 mg/day)
Number of subjects: 93
Study: 26923796

Group type: EXPERIMENTAL
Intervention: Patient decision aid (PDA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Informational resource sheet
Number of subjects: 0
Study: 24487558

Group type: EXPERIMENTAL
Intervention: 2-octyl-cyanoacrylate
Number of subjects: 609

Group type: COMPARATOR
Intervention: metal staples
Number of subjects: 609
Study: 22985001

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (targeting children, parents, and school staff)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Student intervention (targeting only children)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 392
Study: 18083635

Group type: EXPERIMENTAL
Intervention: 50-Pressure group (50mmHg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 150-Pressure group (150mmHg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0-Pressure group (no pressure)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 250-Pressure group (250mmHg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: All groups with vascular occlusion
Number of subjects: 21

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 21
Study: 17965785

Group type: EXPERIMENTAL
Intervention: Isothermic carbon dioxide (37 degrees C)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Hypothermic carbon dioxide (21 degrees C)
Number of subjects: 62
Study: 15499763

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate lotion
Number of subjects: 222

Group type: COMPARATOR
Intervention: Clobetasol propionate cream
Number of subjects: 222

Group type: COMPARATOR
Intervention: Vehicle lotion
Number of subjects: 222
Study: 11549974

Group type: EXPERIMENTAL
Intervention: rizatriptan 10‐mg wafer
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: rizatriptan 5‐mg wafer
Number of subjects: 458

Group type: COMPARATOR
Intervention: standard care
Number of subjects: 458
Study: 9715738

Group type: EXPERIMENTAL
Intervention: 10-s sprint
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 20-s sprint
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 30-s sprint after 10-s sprint
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 30-s sprint after 20-s sprint
Number of subjects: 8
Study: 8150244

Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0
Study: 2906290

Group type: EXPERIMENTAL
Intervention: Oral yohimbine (0.2 mg kg-1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol (0.5 mg kg-1; 60 min before yohimbine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-meal condition
Number of subjects: 0
Study: 29848211

Group type: EXPERIMENTAL
Intervention: Cycling at 80% of VO2max for 50 minutes
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Exhausting running
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Exhausting cycling
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Graded exercise (cycling and running) until exhaustion
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 33
Study: 26482233

Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 2293

Group type: EXPERIMENTAL
Intervention: ATRIA score
Number of subjects: 2293

Group type: EXPERIMENTAL
Intervention: ORBIT score
Number of subjects: 2293

Group type: EXPERIMENTAL
Intervention: ATRIA and ORBIT scores
Number of subjects: 2293
Study: 25271544

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 11997

Group type: COMPARATOR
Intervention: Selective oropharyngeal decontamination (SOD)
Number of subjects: 11997
Study: 22925198

Group type: COMPARATOR
Intervention: mADM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mADM plus MBCT
Number of subjects: 0

Group type: COMPARATOR
Intervention: MBCT
Number of subjects: 0
Study: 19930765

Group type: EXPERIMENTAL
Intervention: Berry purée with 35 g sucrose
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control sucrose load
Number of subjects: 12
Study: 18842125

Group type: EXPERIMENTAL
Intervention: Strength training (progressive functional strength training program)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 51
Study: 15933563

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (90/6.4 mg/kg/d in 2 divided doses for 10 days)
Number of subjects: 730

Group type: COMPARATOR
Intervention: Azithromycin (10 mg/kg for 1 day followed by 5 mg/kg/d for 4 days)
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate
Number of subjects: 730

Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 730
Study: 12124714

Group type: EXPERIMENTAL
Intervention: Diamond laser scalpel
Number of subjects: 18

Group type: COMPARATOR
Intervention: Steel scalpel with electrocoagulation
Number of subjects: 18
Study: 10747531

Group type: EXPERIMENTAL
Intervention: Telemonitoring (daily collection of blood pressure, pulse, and weight data; weekly video conference with nurse)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (blood pressure, weight, and pulse measured at six weekly intervals)
Number of subjects: 20
Study: 8751028

Group type: EXPERIMENTAL
Intervention: Flunarizine (open-label)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Higher doses of flunarizine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 16
Study: 2096499

Group type: EXPERIMENTAL
Intervention: Mefloquine 25 mg/kg body weight single dose
Number of subjects: 113

Group type: COMPARATOR
Intervention: Chloroquine 25 mg/kg body weight over 3 days
Number of subjects: 113
Study: 866041

Group type: EXPERIMENTAL
Intervention: Cold pressor immersion of the hand
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cold pressor immersion of the finger
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 80
Study: 31943069

Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy (DC) performed after 48 hours since stroke diagnosis
Number of subjects: 66

Group type: COMPARATOR
Intervention: Decompressive craniectomy (DC) performed within 48 hours since stroke diagnosis
Number of subjects: 66
Study: 30337172

Group type: EXPERIMENTAL
Intervention: Inactivated monovalent influenza A/H1N1 vaccine (IIV), two doses administered three weeks apart
Number of subjects: 48
Study: 25920528

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 692
Study: 25048074

Group type: EXPERIMENTAL
Intervention: Eccentric load at 138% of concentric load
Number of subjects: 40

Group type: COMPARATOR
Intervention: Eccentric load at 0%, 33%, 66%, and 100% of concentric load
Number of subjects: 40

Group type: COMPARATOR
Intervention: Eccentric load at 0%
Number of subjects: 40
Study: 22147839

Group type: EXPERIMENTAL
Intervention: Anatomic ablation of ganglionated plexi (GP) in the right atrium
Number of subjects: 34

Group type: COMPARATOR
Intervention: Selective ablation procedure targeting vagal reflex
Number of subjects: 34
Study: 20697291

Group type: EXPERIMENTAL
Intervention: Mixed Lactobacillus plantarum LP01 and Bifidobacterium breve BR03 (2.5 x 10 colony-forming units/d of each strain)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subspecies lactis BS01 (5 x 10 colony-forming units/d)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 18188760

Group type: EXPERIMENTAL
Intervention: Gain-framed message intervention
Number of subjects: 249

Group type: COMPARATOR
Intervention: Loss-framed message intervention
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: High perceived risk of quitting
Number of subjects: 249
Study: 16193197

Group type: EXPERIMENTAL
Intervention: Walnuts (20 grams per day for 8 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no walnuts)
Number of subjects: 52
Study: 12642354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Low-dose rhVEGF (17 ng x kg(‐1) x min(‐1))
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: High-dose rhVEGF (50 ng x kg(‐1) x min(‐1))
Number of subjects: 178
Study: 10590183

Group type: EXPERIMENTAL
Intervention: Eptifibatide (Integrilin) administered with tissue plasminogen activator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eptifibatide (Integrilin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heparin-treated patients
Number of subjects: 0
Study: 9081272

Group type: EXPERIMENTAL
Intervention: Salbutamol (S) 200 micrograms via inhaler 15 minutes prior to exercise
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 17
Study: 8168235

Group type: EXPERIMENTAL
Intervention: pyquiton at a single dose of 10.5 mg/kg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: pyquiton at a single dose of 2.5 mg/kg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: pyquiton at a single dose (not specified)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: pyquiton (not specified dosage)
Number of subjects: 200
Study: 3021082

Group type: EXPERIMENTAL
Intervention: Concomitant administration of naloxone hydrochloride and yohimbine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naloxone hydrochloride alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yohimbine hydrochloride alone
Number of subjects: 0